Zuprevo from Merck
Merck Animal Health announces the US approval of ZUPREVOTM (tildipirosin) – a novel, new macrolide antibiotic for the management of bovine respiratory disease (BRD). ZUPREVO is indicated for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in beef cattle, and for the control of respiratory disease in cattle at high risk of developing BRD. Tildipirosin also has the lowest single dose volume of any BRD treatment available – 1 mL per 100 lbs. of bodyweight, subcutaneously, with a maximum injection volume of 10 mL per injection site.